CLCM
AUPH icon

Crawford Lake Capital Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Crawford Lake Capital Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-40,800
Closed -$292K – 118
2017
Q1 		$292K Buy
+40,800
New +$188K 0.12% 63

Other funds holding AUPH

HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Crawford Lake Capital Management's AUPH Position: Q1 2020 in Review

Crawford Lake Capital Management sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2020, closing a stake of 358,082 shares — an estimated $7.25M sold.

Crawford Lake Capital Management first reported a position in AUPH in Q1 2017 and held it in 4 quarters. The position peaked at $7.25M in Q4 2019. 125 funds tracked by Wall St. Rank hold AUPH as of Q1 2020.

  • Crawford Lake Capital Management reported no remaining Aurinia Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Crawford Lake Capital Management sold 358,082 Aurinia Pharmaceuticals shares in Q1 2020, an estimated $7.25M.
  • Crawford Lake Capital Management first reported a position in Aurinia Pharmaceuticals in Q1 2017 and held it in 4 quarters.
  • Crawford Lake Capital Management's Aurinia Pharmaceuticals position peaked at $7.25M in Q4 2019.
  • 125 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2020.

Based on Crawford Lake Capital Management's 13F filing for Q1 2020, filed 15 May 2020.